['acute myocardial infarction']
['anakinra 100 mg', 'anakinra 100 mg', 'placebo']

        INCLUSION CRITERIA:

        In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria and
        NONE of the Exclusion criteria.

          1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and
             ECG evidence of ST segment elevation (>1 mm) in 2 or more anatomically contiguous
             leads that is new or presumably new

          2. Planned or completed coronary angiogram for potential intervention

          3. Age>21

        EXCLUSION CRITERIA:

          -  Inability to give informed consent

          -  Pregnancy

          -  Preexisting congestive heart failure (American Heart Association/American College of
             Cardiology class C-D, New York Heart Association III-IV)

          -  Preexisting severe left ventricular dysfunction (EF<20%)

          -  Preexisting severe valvular heart disease

          -  Active infections (acute or chronic) - excluding Hepatitis C Virus (HCV)+ with
             undetectable RNA

          -  Recent (<14 days) or active use of anti-inflammatory drugs (not including
             non-steroidal anti-inflammatory drugs [NSAIDs] or corticosteroids used for IV dye
             allergy only)

          -  Chronic inflammatory disease (including but not limited to rheumatoid arthritis,
             systemic lupus erythematosus)

          -  Active malignancy - excluding carcinoma in situ [any organ] and non-melanoma skin
             cancer

          -  Anticipated need for cardiac surgery

          -  Neutropenia (absolute neutrophil count<1,800/mm3)
      